Evidence-informed medical pharmacology article updated 10 November 2026. For education; prescribing requires current local labeling and individual patient assessment.
Overview and clinical role
Enoxaparin is a low-molecular-weight heparin (LMWH) used to prevent and treat venous thromboembolism and in selected acute coronary syndrome regimens. It is an anticoagulant, not a thrombolytic, and does not directly dissolve existing thrombi. The indication, patient weight, kidney function, bleeding risk and procedure timing determine the regimen [1,2].
Composition and antithrombin mechanism
Enoxaparin is produced by controlled depolymerization of heparin and consists of sulfated glycosaminoglycan chains with an average molecular weight near 4.5 kDa. An antithrombin-binding pentasaccharide motif accelerates inactivation of factor Xa; only sufficiently long chains can simultaneously bridge antithrombin and thrombin. Consequently, anti-Xa activity exceeds anti-IIa activity, unlike unfractionated heparin. A routine fall in aPTT is neither the principal expected effect nor a reliable method of monitoring enoxaparin [1,2].
Administration and pharmacokinetics
Enoxaparin is usually injected subcutaneously into abdominal tissue; approved IV use exists in particular STEMI/PCI protocols. It has more predictable subcutaneous bioavailability than unfractionated heparin, with renal elimination important to active anti-Xa exposure. Protamine only partially neutralizes enoxaparin anti-Xa activity; it is not a fully reliable antidote [1,2].
Examples of adult dosing and renal modification
For some labeled adult indications, DVT/PE treatment uses 1 mg/kg subcutaneously every 12 hours, while selected situations use 1.5 mg/kg once daily; these alternatives are not interchangeable in every patient. Prophylaxis doses vary substantially by surgery/medical indication, often 40 mg once daily or 30 mg twice daily. With creatinine clearance below 30 mL/min, the US label lists 30 mg subcutaneously once daily for several prophylaxis indications and 1 mg/kg once daily for some acute DVT treatment scenarios. STEMI and advanced-age regimens require separate adjustments. These are illustrative labeling examples, not prescribing directions for an individual [2].
Monitoring and safety
Check CBC/platelets, renal function and bleeding signs. Routine anti-Xa testing is unnecessary for most adults but may be considered selectively in renal impairment, pregnancy, very low/high body weight or other complex settings; ranges depend on indication and sampling time. Heparin-induced thrombocytopenia may occur and requires prompt assessment when suspected. Active major bleeding and recent immune-mediated heparin-induced thrombocytopenia are important contraindications [1,2].
Neuraxial, pregnancy and interactions
Enoxaparin carries a boxed warning about spinal/epidural hematoma during spinal puncture or neuraxial anesthesia. Timing of catheter placement/removal and restarting the anticoagulant depends on dose, renal function and current anesthesia guidance; neurological deficits after neuraxial procedures require immediate evaluation. Concurrent aspirin, antiplatelets, NSAIDs or other anticoagulants increase bleeding risk. LMWH is frequently preferred in pregnancy when therapeutic anticoagulation is needed, but pregnant patients with mechanical valves need specialized management [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Enoxaparin sodium injection, USP: prescribing information, including renal dose adjustment and boxed neuraxial hematoma warning. US National Library of Medicine. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e0ac5e2-329c-d0a8-e063-6394a90afba8
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.